FDA Uses Agentic AI to Speed Up Tobacco PMTA Reviews
The U.S. Food and Drug Administration (FDA) has officially launched the widespread implementation of “agentic AI” capabilities, aiming to modernize and accelerate its regulatory workflows, including the review of premarket tobacco product applications (PMTA). FDA Commissioner Marty Makary described this as a significant modernization effort to equip reviewers with the best possible tools.
These advanced AI systems, capable of planning and executing multi-step tasks, are designed to support various functions such as premarket reviews, post-market surveillance, inspections, and compliance. The agency emphasized that these tools operate within a secure government cloud and are not trained on industry-submitted data, ensuring the protection of sensitive regulatory information.
Crucially, the FDA clarified that while these tools can streamline work, they do not replace human judgment. An agency spokesperson stated, “All outputs from AI are reviewed and validated by FDA staff before being incorporated into any official regulatory action.” This human-in-the-loop approach addresses concerns about the potential unpredictability of agentic AI.
This rollout follows the successful launch of the generative AI system “Elsa,” now used by over 70% of FDA staff for tasks like summarizing documents and targeting inspections. Jeremy Walsh, the FDA’s Chief AI Officer, noted that agentic AI will further help ensure the safety and efficacy of regulated products, including tobacco and nicotine items.
- Read more: FDA Authorized E-Cigarette List: What’s Really Included?
- Press source: FDA Expands Artificial Intelligence Capabilities with Agentic AI Deployment
- South Korea Escalates Tobacco Warnings with Blunt, Fatalistic Labels - June 22, 2026
- Magnolia Commissioner Proposes Ordinance to Ban Vape Shops - June 22, 2026
- Belarus Moves to Ban Vape and E-Cigarette Advertising Under New Bill - June 22, 2026









